Page 94 - 79_04

Péptidos,
lagartos
y
diseño
de
fármacos…

20. Kirkpatrick,
A.;
Heo,
J.;
Abrol,
R.;
Goddard
III,
W.
A.
(2012).
Predicted
structure
of
agonist-­-
bound
glucagon-­-like
peptide
1
receptor,
a
class
B
G
protein-­-coupled
receptor.
P.
Natl.
Acad.

Sci.
USA
109,
19988–19993.

21. Runge,
S.;
Thøgersen,
H.;
Madsen,
K.;
Lau,
J.;
Rudolph,
R.
(2008)
Crystal
structure
of
the

ligand-­-bound
Glucagon-­-Like
Peptide-­-1
receptor
extracellular
domain.
J.
Biol.
Chem.
283,

11340-­-11347.

22. Rosenstock,
J.;
Balas,
B.;
Charbonnel,
B.;
Bolli,
G.
B.;
Boldrin,
M.;
Ratner,
R.;
Balena,
R.

(2013)
The
fate
of
taspoglutide,
a
weekly
GLP-­-1
receptor
agonist,
versus
twice-­-daily

exenatide
for
type
2
diabetes:
The
T-­-emerge
2
trial.
Diabet.
Care
36,
498-­-504.

23. Garber,
A.
J.
(2011).
Long-­-acting
Glucagon-­-Like
Peptide
1
receptor
agonists.
Diabet.
Care

34(S2),
S-­-279-­-S284.

24. Kratz,
F.
Albumin
as
a
drug
carrier:
Design
of
prodrugs,
drug
conjugates
and
nanoparticles

(2008).
J.
Control.
Release
132,
171-­-183.

25. Nauck,
M.;
Petrie,
J.
R.;
Sesti,
G.;
Mannucci,
E.;
Courreges,
J.-­-P.;
Atkin,
R.;
Düring,
S.;
Jensen,

M.;
Heller,
C.
B.
(2012).
The
once-­-weekly
human
GLP-­-1
analogue
semaglutide
provides

significant
reductions
in
HbA1c
and
body
weight
in
patients
with
type
2
diabetes.

Diabetologia
55
(Suppl.
1),
S7.

26. http://clinicaltrials.gov/ct2/show/NCT00804986
(consultado
el
07-­-08-­-2013).

27. Czajkowsky,
D.
M.;
Hu,
J.;
Shao,
Z.;
Pleass,
R.
J.
(2012).
Fc-­-fusion
proteins:
new

developments
and
future
perspectives
EMBO
Mol.
Med.
4,
1015–1028.

28. Glaesner,
W.;
Vick,
A.
M.;
Millican,
R.;
Ellis,
B.;
Tschang,
S.
H.;
Tian,
Y.;
Bokvist,
K.;
Brenner,

M.;
Koester,
A.;
Porksen,
N.;
Etgen,
G.;
Bumol,
T.
(2011).
Engineering
and
characterization

of
the
long-­-acting
Glucagon-­-Like
Peptide-­-1
analogue
LY2189265,
an
Fc
fusion
protein.

Diabetes
Metab.
Res.
Rev.
26,
287–296.

29. Schellenberger,
V.;
Wang,
C.
W.;
Geething,
N.
C.;
Spink,
B.
J.;
Campbell,
A.;
To,
W.;
Scholle,
M.

D.;
Yin,
Y.;
Yao,
Y.;
Bogin,
O.;
Cleland,
J.
L.;
Silverman,
J.;
Stemmer,
W.
P.
C.
(2009).
A

recombinant
polypeptide
extends
the
in
vivo
half-­-life
of
peptides
and
proteins
in
a
tunable

manner.
Nat.
Biotechnol.
27,
1186
–
1190.

30. http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3217&sKey=0687e7c8-­-
c97d-­-442b-­-92ec-­-ae505e051854&cKey=66ccf402-­-dd78-­-4894-­-8cae-­-
b259fba97022&mKey=%7B89918D6D-­-3018-­-4EA9-­-9D4F-­-711F98A7AE5D%7D

(consultado
el
12-­-08-­-2013).

31. Russell-­-Jones,
D.;
Gough,
S.
(2012).
Recent
advances
in
incretin-­-based
therapies.
Clin.

Endocrinol.
77,
489–499.

32. Sivertsen,
J.;
Rosenmeier,
J.;
Holst,
J.
J.;
Vilsbøll,
V.
(2012).
The
effect
of
Glucagon-­-Like

Peptide
1
on
cardiovascular
risk.
Nat.
Rev.
Cardiol.
9,
209-­-222.

33. Cai,
Y.;
Wei,
L.;
Ma,
L.;
Huang,
X.;
Tao,
A.;
Liu,
Z.;
Yuan,
W.
(2013).
Long-­-acting
preparations

of
exenatide.
Drug
Des.
Devel.
Ther.
2013:7
963–970.

34. Ballav,
C.;
Gough,
S
(2012).
Bydureon:
long-­-acting
exenatide
for
once-­-weekly
injection.

Prescriber
23,
30-­-33.

35. Krause,
A.
(2011).
Exenatide
LAR:
A
sustained-­-release
formulation
of
exenatide
for
the

treatment
of
type
2
diabetes.
Formulary
45,
43-­-51.

36. DeYoung,
M.
B.;
MacConell,
L.;
Sarin,
V.;
Trautmann,
M.;
Herbert,
P.
(2012).
Encapsulation

of
exenatide
in
poly-­-(D,L-­-lactide-­-co-­-glycolide)
microspheres
produced
an
investigational

long-­-acting
once-­-weekly
formulation
for
type
2
diabetes.
Diabet.
Technol.
Ther.
13,
1145-­-
1154.

37. http://clinicaltrials.gov/show/NCT01104701
(consultado
el
20-­-08-­-2013).

38. Rohloff,
C.
M.;
Alessi,
T.
R.;
Yang,
B.;
Dahms,
J.;
Carr,
J.
P.;
Lautenbach,
S.
D.
(2008).
DUROS®

technology
delivers
peptides
and
proteins
at
consistent
rate
continuously
for
3
to
12

months.
J.
Diabetes
Sci.
Technol.
2,
461-­-467.

39. Henry,
R.
D.;
Rosenstock,
J.;
Logan,
D.
K.;
Alessi,
T.
R.;
Luskey,
K.;
Baron,
M.
A.
(2013).

Randomized
trial
of
continuous
subcutaneous
delivery
of
exenatide
by
ITCA
650
versus

twice-­-daily
exenatide
injections
in
metformin-­-treated
type
2.
Diabetes
Care
36,
doi:

10.2337/dc12-­-2410.

40. http://www.emisphere.com/barriers_oral_delivery.html
(consultado
el
02-­-08-­-2013).

41. Thoma,
R.;
Löffler,
B.;
Stihle,
M.;
Huber,
W.;
Ruf,
A.;
Hennig,
M.
(2003).
Structural
basis
of

proline-­-specific
exopeptidase
activity
as
observed
in
human
Dipeptidyl
Peptidase-­-IV.

Structure
11,
947–959.

611